Atlantic Pharmaceuticals Inc. preclinical data

ATLC presented preclinical evidence that a non-psychoactive cannabis mimic acts at prostaglandin receptors to modulate inflammation. As reported at the International Conference on Prostaglandins and Related Compounds in Vienna, CT-3 reduced paw edema in mice, a model of inflammatory responses. In the hot plate assay, an analgesic indicator, 25 µg of compound increased the latency to flinch. At similar doses, it also reduced by 50 percent the effects of adjuvant-induced arthritis in rats.

No catalepsy (diminished response) was seen in mice, even at 40 times the therapeutic dose, suggesting a lack of central nervous system action. ...